Table 2 Peripheral blood stem cell mobilization characteristics

From: Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma

Characteristics R-patients (n=23) Non-R patients (n=20) P
Duration from HD-VP to collection of PBSC, median days (range) 20 (16–22) 20 (15–21) 0.36
WBC count at PBSC collection, mean (range) ( × 109/l) 9.49±4.17 (4.30–18.26) 8.72±4.51 (3.70–19.30) 0.55
Neutrophil count at PBSC collection, mean (range) ( × 109/l) 7.07±4.14 (1.70–16.25) 6.33±4.29 (1.67–16.87) 0.44
Platelet count at PBSC collection, mean (range) ( × 109/l) 168.1±85.2 (49.3–373.0) 188.7±97.4 (37.3–282.7) 0.29
CD34+ cell dose collected in PBSC ( × 106/kg), mean (range) 11.10±8.04 (2.23–27.9) 13.00±10.30 (6.35–51.00) 0.64
Percent of CD34+ cells per PBSC MNC, mean (range) 3.66±3.27 (0.52–16.1) 3.98±2.09 (1.52–10.71) 0.85
Percent of CD19+ B-cells per PBSC MNC, mean (range)a 0.06±0.05 (0.013–0.150) 0.89±0.39 (0.50–1.46) <0.005
  1. Abbreviations: R=rituximab; HD-VP=high-dose etoposide for PBSC mobilization; NS=not significant (P>0.05).
  2. aContent of CD19+ B cells was analyzed in seven R-patients and seven non-R patients, respectively.